p21/WAF1 expression as related to p53, cell proliferation and prognosis in epithelial ovarian cancer

Ma, Anttila; Kosma, Veli‐Matti; Hongxiu, J; Puolakka, Jukka; Juhola, Martti; Saarikoski, Seppo; Syrjänen, Karí

doi:10.1038/sj.bjc.6690298

Cited by 88 publications

(86 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…This is consistent with findings from several other studies (Baekelandt et al, 1999a(Baekelandt et al, , 1999bDiebold et al, 1996;Herod et al, 1996;Marone et al, 1998) although an inverse correlation between TP53 and BCL-2 (Henriksen et al, 1995) and between TP53 and p21 (Anttila et al, 1999) has also been reported in ovarian tumour tissues. The lack of a correlation between TP53 and its downstream genes may reflect the fact that expression of these genes is also regulated by TP53-independent pathways.…”

Section: Discussionsupporting

confidence: 92%

“…This is in agreement with a recent report that also failed to find an association between p21 expression and prognosis or response to platinum-based chemotherapy in specimens from stage III ovarian cancer patients (Baekelandt et al, 1999a). In contrast to these findings Anttila et al (1999) reported that low p21 expression, using a polyclonal antibody, is a marker of poor overall survival.…”

Section: Discussionmentioning

confidence: 66%

See 1 more Smart Citation

Reduced expression of BAX is associated with poor prognosis in patients with epithelial ovarian cancer: a multifactorial analysis of TP53, p21, BAX and BCL-2

Schuyer¹,

Burg²,

Henzen‐Logmans

et al. 2001

Br J Cancer

View full text Add to dashboard Cite

Summary Traditional clinicopathological features do not predict which patients will develop chemotherapy resistance. The TP53 gene is frequently altered in ovarian cancer but its prognostic implications are controversial. Little is known on the impact of TP53-downstream genes on prognosis. Using molecular and immunohistochemical analyses we examined TP53 and its downstream genes p21, BAX and BCL-2 in ovarian tumour tissues and have evaluated the results in relation to clinico-pathological parameters, clinical outcome and response to platinum-based chemotherapy. Associations of tested factors and patient and tumour characteristics were studied by Spearman rank correlation and Pearsons χ 2 test. The Cox proportional hazard model was used for univariate and multivariate analysis. The associations of tested factors with response was tested using logistic regression analysis. TP53 mutation, p21 and BCL-2 expression were not associated with increased rates of progression and death. Expression of TP53 was associated with a shorter overall survival only (relative hazard rate [RHR] 2.01, P = 0.03). Interestingly, when combining TP53 mutation and expression data, this resulted in an increased association with overall survival (P = 0.008). BAX expression was found to be associated with both progression-free (RHR 0.44, P = 0.05) and overall survival (RHR 0.42, P = 0.03). Those patients who simultaneously expressed BAX and BCL-2 had a longer progression-free and overall survival compared to patients whose tumours did not express BCL-2 (P = 0.05 and 0.015 respectively). No relations were observed between tested factors and response to platinum-based chemotherapy. We conclude that BAX expression may represent a prognostic indicator for patients with ovarian cancer and that the combined evaluation of BAX and BCL-2 may provide additional prognostic significance.

show abstract

Section: Discussionsupporting

confidence: 92%

Section: Discussionmentioning

confidence: 66%

Reduced expression of BAX is associated with poor prognosis in patients with epithelial ovarian cancer: a multifactorial analysis of TP53, p21, BAX and BCL-2

Schuyer¹,

Burg²,

Henzen‐Logmans

et al. 2001

Br J Cancer

View full text Add to dashboard Cite

show abstract

“…Some of the examples in Table 3 illustrate the concordance in microarray analysis with previous published reports based on Northern blot analysis and immunohistochemistry. In particular, both CDKN1A (Anttila et al, 1999) and SPARC (Mok et al, 1996) have been shown to be down-regulated in aggressive ovarian cancer and this mirrors the situation revealed by microarray expression analysis in our model. Once again, for these genes the pattern of expression of NOV-31 and TOV-81D are highly similar, and contrast sharply with the aggressive EOC samples.…”

Section: Discussionsupporting

confidence: 60%

“…It is possible to compare the expression pattern of genes previously described in ovarian cancer (Anttila et al, 1999;Asschert et al, 1997;Barboule et al, 1998;Brown et al, 1999;Chambers et al, 1998;Courjal et al, 1996;Huleihel et al, 1997;Mok et al, 1996;Neyns et al, 1996;Tanner et al, 1998;Wysocki et al, 1990) with the expression values generated by microarray analysis. Some of the examples in Table 3 illustrate the concordance in microarray analysis with previous published reports based on Northern blot analysis and immunohistochemistry.…”

Section: Discussionmentioning

confidence: 99%

Microarray analysis of gene expression mirrors the biology of an ovarian cancer model

et al. 2001

View full text Add to dashboard Cite

“…Elsewhere p21 induction has been observed to be p53-independent in breast cancer (Rey et al, 1998), ovarian cancer (Elbendary et al, 1996;Anttila et al, 1999) and in human leukaemia . Our results suggested a p53-independent mechanism of p21 activation only in a subgroup of patients (Table 3).…”

Section: Discussionmentioning

confidence: 99%

p21/WAF1 expression in human colorectal carcinoma: association with p53, transcription factor AP-2 and prognosis

et al. 1999

Self Cite

View full text Add to dashboard Cite

p21/WAF1 expression was studied in a series of 162 colorectal carcinoma patients and its relation to p53- and activator protein (AP)-2 expressions and to stage as well as survival was assessed. p21 expression was moderate or intense in 33% of the tumours, and 53% of the tumours had moderate or strong p53 staining intensity. Eighty-nine percent of the tumours showed a weak cytoplasmic AP-2 signal. As expected, p21 and p53 stainings were inversely related to each other ( P < 0.001). There was a significant positive association between p21 and AP-2 expression levels ( P = 0.01). p21 intensity and percentage were higher in Dukes' A and B stages ( P < 0.001). The cancer-related survival and recurrence-free survival (RFS) rates were significantly lower among patients with a low signal for p21 ( P < 0.001) and low p21 percentage in tumour epithelium ( P < 0.001). High p53 staining intensity in tumour epithelium predicted poor survival ( P = 0.01) and RFS ( P = 0.003). In the multivariate analysis, p21 percentage distribution independently predicted cancer-related survival in all cases, and p21 expression intensity in T1–4/N0–3/M0 and T1–3/N0/M0 cases. p21 percentage distribution was an independent predictor of RFS in all and T1–3/ N0/M0 cases. AP-2 staining did not reach any prognostic significance. These results suggest that the immunohistochemical detection of cyclin-dependent kinase inhibitor p21 could be used to predict more precisely the outcome of colorectal cancer patients. © 1999 Cancer Research Campaign

show abstract

p21/WAF1 expression as related to p53, cell proliferation and prognosis in epithelial ovarian cancer

Cited by 88 publications

References 36 publications

Reduced expression of BAX is associated with poor prognosis in patients with epithelial ovarian cancer: a multifactorial analysis of TP53, p21, BAX and BCL-2

Reduced expression of BAX is associated with poor prognosis in patients with epithelial ovarian cancer: a multifactorial analysis of TP53, p21, BAX and BCL-2

Microarray analysis of gene expression mirrors the biology of an ovarian cancer model

p21/WAF1 expression in human colorectal carcinoma: association with p53, transcription factor AP-2 and prognosis

Contact Info

Product

Resources

About